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Purpose: Retinitis pigmentosa (RP) is caused by mutations in a variety of genes, most of which have known functions in
the retina. However, one of the most perplexing findings of recent retinal genetics research was the discovery of mutations
causing dominant RP in four ubiquitously expressed splicing factors. The aim of this study was to use lymphoblast cell
lines derived from RP patients to determine whether mutations in two of these splicing factors, PRPF8 and PRPF31, cause
measurable deficiencies in pre-mRNA splicing.
Methods: cDNA was prepared from lymphoblastoid cell lines derived from RP patients bearing mutations in the splicing
factor genes and controls, grown under a variety of conditions. Introns representing the U2 and U12 intron classes, with
both canonical and noncanonical donor and acceptor sequences, were analyzed by real-time PCR to measure the ratio of
spliced versus unspliced transcripts for these introns. In addition, plasmids encoding the retinal outer segment membrane
protein-1 (ROM-1; exon 1 to exon 2) gene, both in the wild-type form and with mutations introduced into the splice donor
sites, were transfected into cell lines. The spliced versus unspliced cDNA ratios were measured by real-time RT–PCR.
Results: Splicing of four canonical U2 introns in the actin beta (ACTB), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), PRPF8, and retinitis pigmentosa GTPase regulator (RPGR) genes was unaffected in PRPF8 mutant cells.
However, the splicing efficiency of RPGR intron 9 was significantly decreased in PRPF31 mutant cell lines. In contrast,
a consistent decrease in the splicing efficiency of all U12 and noncanonical U2 introns was seen in PRPF8, but not in
PRPF31, mutant cells, with statistical significance for STK11 intron 3.
Conclusions: In spite of the ubiquitous expression patterns of the genes implicated in splicing factor RP, no pathology
has yet been documented outside the retina. The observed differences in splicing efficiency described herein favor the
hypothesis that these mutations may have a subpathological effect outside the retina. These observations argue against a
defect in some yet to be discovered additional function of these proteins and support the alternative hypothesis that this
form of RP does indeed result from aberrant splicing of retinal transcripts.
Retinitis pigmentosa (RP) is the most common form of
hereditary retinal degeneration, occurring in around 1 in 3,500
people [1]. It is characterized by progressive degeneration of
the peripheral retina (leading to night blindness), loss of the
peripheral visual fields, and an abnormal electroretinogram.
RP is clinically and genetically heterogeneous, with all three
modes  of  Mendelian  inheritance:  autosomal  dominant  RP
(adRP), autosomal recessive RP (arRP), X-linked RP (xlRP),
as well as mitochondrial inheritance running in families. To
date some 47 loci have been identified for nonsyndromic RP
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and for these 36 of the causative genes have been identified
(see  RetNet  for  full  list).  These  include  genes  encoding
components of the phototransduction cascade and the visual
cycle, by which the chromophore component of rhodopsin is
recycled, as well as retinal transcription factors, structural
proteins, and proteins thought to be involved in intracellular
transport within photoreceptors [2]. In addition, mutations in
four  ubiquitously  expressed  splicing  factors,  pre-mRNA
processing factor 8 (PRPF8 [3]), PRPF31 [4], PRPF3 [5], and
PIM1  associated  protein  (PAP-1)  [6,7]  have  also  been
described in dominant RP patients [8]. Patients with splicing
factor  mutations  do  not  appear  to  exhibit  any  disease
phenotype other than retinal degeneration, and the basis of this
specificity remains to be determined.
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2357Splicing is a complex process that results in the precise
excision of introns from pre-mRNA by a macromolecular
structure  called  the  spliceosome  [9,10].  The  majority  of
introns are spliced by the major (U2-dependent) spliceosome,
which consists of auxiliary protein factors and four small
nuclear ribonucleoprotein particles (snRNPs): U1, U2, U5,
and U4/U6. However, a small percentage of introns (about 1
in 700 for primates) [11] are spliced by the minor (U12-
dependent)  spliceosome,  which  differs  from  the  major
spliceosome in four of the snRNPs it contains (U11, U12,
U4atac, and U6atac with canonical U5). Signals in intron and
exon sequences further define intron and exon recognition and
the  execution  of  splicing.  In  both  U2  and  U12  introns,
canonical  (GT/AG)  and  various  noncanonical  consensus
splice site sequences are used. U12-dependent introns are
characterized by a more highly conserved branch site and lack
of a polypyrimidine tract [12,13]. It has been suggested that
the splicing of U12-dependent introns may be a rate-limiting
step in gene expression [14].
PRPF8 is a 220 kDa protein that is highly conserved both
in sequence and size, varying between 220 and 280 kDa in
different organisms. It is a component of the U5snRNP and
U5·U4/U6  tri-snRNP  [15].  PRPF8  can  also  be
photochemically  cross-linked  to  the  5′  splice  site,  the
branchpoint and the 3′ splice site in the pre-mRNA [16–18]
and to the U5 and U6 snRNAs [19,20]. PRPF8 is therefore
thought to be at the catalytic center of the spliceosome [21,
22]. This close association with crucial RNA sequences and
proteins  in  the  spliceosome  suggests  that  PRPF8  could
directly affect the function of the catalytic core, perhaps acting
as  a  splicing  cofactor.  Unlike  most  other  known  splicing
factors, as a component of the U5 snRNPs, PRPF8 participates
in both U2 and U12 splicing [15].
Mutations in PRPF8 cause a severe form of dominant RP
[3].  To  date,  16  different  mutations,  including  missense,
premature stop and deletions, have been identified [3,23–26].
They cluster in a highly conserved region within the last exon,
encoding the C-terminus of the protein, making it unlikely that
these transcripts will be removed by nonsense-mediated decay
[27]. This is supported by real-time PCR analysis that has
shown similar expression of both wild-type and mutant alleles
in cell lines from RP patients carrying a nonsense mutation
[28].  This  remarkable  clustering  of  mutations  and  the
relatively high number of missense changes could imply that
the mutations alter a specific domain of particular importance
to retinal function. Crystal structural analysis of the last 273
amino acids of Caenorhabditis elegans PRPF8 shows that the
RP mutations are contained in a C-terminal extension that is
not thought to affect the overall structure of this domain [29].
However,  it  is  hypothesized  that  the  C-terminal  peptide
(2310–2335)  constitutes  a  direct  binding  surface  between
PRPF8 and other partners, and mutations on this surface could
therefore  lead  to  disruption  of  critical  protein–protein
interactions necessary for function [29], a finding recently
confirmed by Boon et al. [30].
PRPF31 is a 61 kDa splicing factor first identified in yeast
[31]. It is a U4/U6 snRNP-associated protein that promotes
tri-snRNP association between U4/U6 snRNP and U5 snRNP
by direct interactions with a 102 kDa U5-specific protein
[32]. At present, there are 19 known RP-causing mutations in
PRPF31. Only three of these are missense changes while the
remainder  encode  severely  truncated  or  grossly  abnormal
transcripts (six deletions ranging from one base pair to the
whole gene, five splice-site mutations, two insertion/deletion
events, one duplication, and one insertion) [24,33–41]; these
changes may be targeted by nonsense-mediated decay [27].
In support of this, allele-specific measurement of PRPF31
transcripts have revealed a strong reduction in the expression
of mutant alleles, with no truncated proteins being detected.
Blocking of nonsense-mediated mRNA decay restored the
amount of mutant PRPF31 mRNA but did not restore the
synthesis of mutant proteins [42]. This suggests that mutations
in PRPF31 cause RP due to haploinsufficiency, an observation
further supported by the finding that high-expressing alleles of
PRPF31 from the normal parent compensate for a potentially
RP-causing mutation on the opposite chromosome [43]. This
phenomenon  explains  the  unusually  high  level  of
nonpenetrance  associated  with  RP  due  to  mutations  in
PRPF31 [44].
Three hypotheses can be put forward to explain how
mutations in splicing factors might cause RP in the absence
of any other defect. The first is that mutations specifically
affect the splicing of one or several retina-specific genes. An
obvious target would be rhodopsin (RHO), which makes up
80% of the protein content of the rod outer segment [45]. The
constant process of disc shedding and renewal of the rod outer
segments means that demand for RHO mRNA might be high,
which  could  be  met  through  new  synthesis  as  well  as  a
function  of  mRNA  stability.  Consistent  with  this  first
hypothesis  reduced  splicing  of  an  exon  3–4  minigene
construct of rhodopsin was associated  with cells transfected
with a mutated version of PRPF31 [46].
A second hypothesis would be that mutations cause a
generalized splicing deficiency but this is only pathological
in the fast-metabolizing, end-differentiated retina [47]. This
could be consistent with a defect in the translocation of these
splicing factor proteins to the nucleus, as proposed by Deery
et al. [48], or with a deficit in U12-dependent spliceosome
function, as proposed by McKie et al. [3].
A  third  hypothesis  is  that  PRPF8  and  PRPF31  have
another function unrelated to mRNA splicing, as proposed for
another disease-implicated splicing factor, survival of motor
neuron  1  (SMN1)  [49].  The  finding  of  mutations  in  four
spliceosomal components leading to adRP would however
tend to suggest involvement of the whole tri-snRNP, rather
than separate components of it, in this alternative function.
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2358Hypotheses one and two, that the RP-causing mutations
cause splicing deficiency, may be more consistent with the
haploinsufficiency  mechanism  proposed  for  PRPF31
mutations, rather than the dominant negative effect implied
by the clustered missense mutations found in PRPF8. In this
study we compared the efficiency with which U2 and U12
introns (both canonical and noncanonical) were spliced in cell
lines derived from RP patients carrying PRPF8 or PRPF31
mutations and controls. The study also aimed to determine
whether  RP-causing  mutations  resulted  in  measurable
splicing defects in lymphoblastoid cell lines derived from
these patients.
METHODS
Cell  culture:  Samples  of  blood  from  individuals  carrying
mutations  in  PRPF8  were  collected  by  D.  Mackey
(Melbourne, Australia) and R. Ramesar (Cape Town, South
Africa; see Table 1 for details) and deposited with European
Collection of Cell Cultures (ECACC; Salisbury, UK), where
cell lines were then prepared by EBV transformation. All
individuals  with  PRPF8  mutations  had  RP.  Individuals
recruited were otherwise healthy. Peripheral venous blood
was obtained from patients and other family members by
venepuncture  using  lithium  heparin  or  sodium  citrate
vacutainers. Samples were stored and transported at room
temperature for a maximum of 5 days before immortalisation
with EBV. All blood samples were collected from patients
after obtaining informed consent from each participant and
receiving local ethics committee approval. The remaining cell
lines were obtained directly from ECACC. These included
cell  lines  from  patients  and  asymptomatic  carriers  with
PRPF31 mutations and also unaffected relatives of PRPF31
mutation carriers, who were used as controls. The individuals
from whom these lines were prepared were again otherwise
healthy. Cells were grown in RPMI1640 medium with L-
glutamine  supplemented  with  10%  heat-inactivated  FBS
(Gibco, Carlsbad, CA) at 37 °C in 5% CO2 and maintained
according to ECACC protocols.
RNA  extraction  and  cDNA  synthesis:  Total  RNA  was
extracted  from  pelleted  cells  using  the  Qiagen  RNeasy
extraction kit according to the manufacturer’s protocol. The
process included a 15-min treatment with DNaseI (Qiagen) to
digest any contaminating genomic DNA. Next, 1 µl of RNA
was mixed with 1 µg random primer (Invitrogen, Glasgow,
UK)  and  10  µl  nuclease-free  water.  This  mixture  was
incubated at 70 °C for 10 min and chilled on ice. To each
reaction was added 8 µl of master mix: 4 µl 5X Moloney
Murine Leukemia Virus Reverse Transcriptase (M-MLV RT)
buffer,  2  µl  0.1  M  dithiothreitol  (DTT),  2  µl  10  mM
deoxynucleosides  (dNTPs;  all  Invitrogen),  and  0.25  µl
RNAsin  (Promega,  Hampshire,  UK).  This  then  was
equilibrated at 37 °C for 2 min. Next, 0.5µl Moloney Murine
Leukemia Virus (M-MLV) reverse transcriptase (Invitrogen)
was added to each reaction, followed by incubation at 37 °C
for 1 h and at 95 °C for 5 min. For each cell line a control
cDNA synthesis without reverse transcriptase was performed
and the presence of genomic DNA was excluded by failure to
PCR with GAPDH primers shown in Table 2.
TABLE 1. CELL LINES USED IN THIS STUDY WITH THEIR CORRESPONDING MUTATIONS AND PATIENT CHARACTERISTICS
Group Cell line Mutation Sex Age
Control AG0318 Control M 22
  AG0300 Control F 32
  AG0309 Control F 34
  AG0267 Control M 46
  AG0326 Control F 58
  AG0261 Control F 77
  AGO296 Control F 56
PRPF31 Carrier AG0353 Exon 11, 11 bp Del, nt 1115–1125 M 22
  AG0311 Exon 11, 11 bp Del, nt 1115–1125 F 23
  AG0298 Exon 11, 11 bp Del, nt 1115–1125 M 58
PRPF31 Severe AG0306 Exon 11, 11 bp Del, nt 1115–1125 F 47
  AG0325 Exon 11, 11 bp Del, nt 1115–1125 M 56
  HG0003 IVS 6 +3 A>G F 62
  HG0005 Whole gene deletion F 65
  AG0316 Exon 11, 11 bp Del, nt 1115–1125 F 72
PRPF8 HG0007 H2309P F 33
  HG0008 H2309P F 67
  HG0009 HG0011 HG0012 H2309P F 72
    H2309R F 60
    H2309R F 30
Samples were collected by D.Mackey (Melbourne, Australia), or R.Ramesar (Cape Town, South Africa), or obtained from the
ECACC as stated in Materials and Methods.
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2360Real-time PCR: Ten introns (in ten different genes) were
selected for analysis to represent both U2 and U12 introns with
canonical and noncanonical donor and acceptor sites. Primer
Express 1.5 software (ABI Prism 7000 User’s Guide, Applied
Biosystems, Foster City, CA) was employed to design primer
pairs.  Pairs  spanned  two  adjacent  exons  or  an  exon  and
adjacent intron and were used to amplify a product of 80–140
bp, with an annealing temperature between 58 and 60 °C (see
Table 2 for complete primer list). Primer pair concentrations
were optimized for real-time PCR analysis according to (ABI,
Applied  Biosystems)  recommendations.  GAPDH  and  18S
were  used  as  endogenous  references.  cDNAs  of  highly
expressing  transcripts  were  diluted  to  obtain  comparable
levels of cycle threshold (Ct). Real-time PCR was performed
using the SYBR Green PCR Core Reagents Kit (ABI, Applied
Biosystems)  as  described  by  Ponchel  et  al.  [50],  and  all
samples were run in duplicate on an ABI PrismTM 7700
Sequence Detector System. Expression levels of each exon-
exon and exon-intron were normalized to GAPDH using a
standard ΔCt method.
Statistical analyses: The ratio of spliced to unspliced RNA
was calculated for each data point as relative amount of exon-
exon  product  divided  by  relative  amount  of  exon-intron
product. Descriptive statistics on the ratios for each gene and
cell line were performed and graphs were produced in Excel.
For  each  cell  line  the  replicates  were  replaced  by  their
respective means for four groups: normal cells; those from
PRPF31 mutation carriers without RP; those from affected
patients with PRPF31 mutations; and those with PRPF8-RP.
These were compared using one-way ANOVA to detect any
overall difference between the four groups, and the LSD post-
hoc  multiple  comparison  test  was  applied  to  examine
individual intergroup differences, using the SPSS statistics
base 17.0, SPSS inc, Chicago, IL. In addition, multivariate
tests  were  performed  in  SPSS  to  analyze  inherent  group
differences between the control and the mutant groups for U2
and U12 introns, and further, a one-sided bootstrap test was
performed.
Serum  starvation:  Cells  were  incubated  in  a  serum-free
medium for 24 h. The medium was then replaced with serum-
containing medium. Samples were taken at 0, 2, 4, 6, 12, 24,
and 72 h after another addition of serum. Total RNA was then
extracted and cDNA synthesized for real-time PCR analysis
as described in the previous section.
Transfections: A plasmid minigene containing mouse retinal
outer  segment  membrane  protein-1  (Rom1)  intron  2  was
constructed by Dr J. Wu (Saint Louis University, St. Louis,
MO) and was obtained as a gift from Professor Eric Pierce,
Scheie  Eye  Institute,  Philadelphia,  PA.  Two  donor  site
sequence changes were introduced using the Stratagene (La
Jolla,  CA)  site-directed  mutagenesis  kit  (according  to
manufacturer’s  instructions  as  described  above),  which
altered the wild-type canonical GT site to AT and GA. Cells
were  transfected  using  the  Effectene  transfection  reagent
(Qiagen) following the manufacturer’s protocol.
RESULTS
Pre-mRNA splicing in lymphoblastoid cell lines derived from
patients  with  PRPF8  and  PRPF31  adRP:  To  determine
whether  mutations  in  splicing  factors  associated  with  RP
cause detectable splicing defects in non-retinal tissues, we
obtained  lymphoblastoid  cell  lines  from  four  groups  of
individuals:  RP  patients  carrying  the  H2309P  or  H2309R
mutation in PRPF8; those with the R372_A375delfs mutation
in PRPF31 who have severe RP; those carrying the PRPF31
R372_A375delfs PRPF31 mutation but not manifesting RP
[4]; and controls (see Table 1).
Ten  exon-intron-exon  sequences  were  chosen  for
analysis.  These  included  four  “house-keeping”  genes
containing U2 introns with consensus splice sites, β-actin
(ACTB),  glyceraldehyde  3-phosphate  dehydrogenase
(GAPDH), the splicing factor PRPF8 gene itself, and RPGR,
mutations in which also lead to RP [51–53]. Also included
were two genes containing U2 introns with non-consensus
splice sites, ZNF198 (a zinc-finger protein encoding gene),
and adenine phosphoribosylase (APRT) . Finally four genes
were selected containing U12 introns, one with a consensus
GT/AG splice site from phospholipase C delta (PLCδ), and
three with non-consensus splice sites, serine-threonine kinase
11 (STK11), ras guanine nucleotide releasing factor C3G and
adaptor-related protein complex 2 α-1 (AP2A1; see Table 3).
The U12 introns were chosen from a database of confirmed
U12 introns [54].
The splicing efficiency of these introns in control and
patient  cell  lines  was  determined  by  examining  ratios  of
spliced  versus  unspliced  transcripts  using  real-time  PCR.
Relative levels of exon-exon product were divided by relative
levels  of  exon-intron  product  to  produce  an  estimate  of
splicing efficiency. Values for the three groups of cell lines
were then compared with values obtained in control cell lines,
and  results  analyzed  using  ANOVA  and  LSD  tests  as
TABLE 3. GENES SELECTED FOR ANALYSIS OF SPLICING
Splice site
sequence Gene Exons
U2 GT/AG β-actin 2–3
  GT/AG GAPDH 7–8
  GT/AG PRPF8 25–26
  GT/AG RPGR 10–11;in 9–ex 10
  GC/AG ZNF198 8–9
  GC/AG APRT 2–3
U12 GT/AG PLCδ 3–4
  AT/AC STK11 3–4
  AT/AC C3G 15–16
  AT/AG AP2A1 19–20
This table summarizes gene intron type, splice site sequence
and amplified exon for each gene used in analysis.
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Intron
  typedescribed in the previous section. Results are shown in Figure
1, Figure 2, and Table 4.
U2 introns: No significant differences in splicing ratios were
observed between control and PRPF8 mutant cell lines for any
Figure 1. Splicing ratios of U2. Splicing ratios of U2 containing
introns RPGR (A) and GAPDH (B) RNA in cell lines derived from
control and splicing-factor mutated cell lines. Group 1 represents
controls, group 2 represents PRPF31 carriers, group 3 represents
PRPF31  severe,  and  group  4  represents  PRPF8  cell  lines.  The
splicing ratios were obtained as described in the Methods section.
Means from four to six repeat experiments are shown ±SEM. For
individual cell line characteristics see Table 1.
U2  introns.  There  were  also  no  significant  differences  in
splicing ratios of U2 introns between control cell lines and
those  deriving  from  asymptomatic  patients  with  PRPF31
mutations. In contrast, PRPF31 mutant cell lines from patients
with a severe phenotype showed significantly lower splicing
ratios  for  RPGR  with  respect  to  controls  (Figure  1)  and
significantly higher splicing ratios for GAPDH. These data are
summarized in Table 4.
U12 introns: None of the splicing ratios assayed for U12
introns in PRPF31 mutant cell lines, either those from RP
patients or from asymptomatic carriers, showed significant
differences from those obtained in control cell lines. However,
PRPF8 mutant cells showed significantly decreased splicing
Figure 2. Splicing ratio of U12. Splicing ratio of U12 containing
intron STK11 RNA in cell lines were derived from control and
splicing-factor mutated cell lines. Group 1 represents controls, group
2 represents PRPF31 carriers, group 3 represents PRPF31 severe,
and group 4 represents PRPF8 cell lines. The splicing ratios were
obtained as described in the Methods section. Means from four to six
repeat  experiments  are  shown  ±SEM.  For  individual  cell  line
characteristics see Table 1.
TABLE 4. RATIOS OF SPLICED TO UNSPLICED RNA IN GROUPS OF CONTROL AND SPLICING FACTOR MUTANT CELL LINES FOR
SELECTED PRE-MRNA INTRONS
Intron and
splice site
PRPF31
carrier
PRPF31
 severe                          PRPF8
U2 GT/AG ACTIN 328 406 315 402
U2 GT/AG GAPDH 1683 1385 2993 p<0.05 1433
U2 GT/AG PRPF8 198 173 184 140
U2 GT/AG RPGR 78 105 23 p<0.05 95
U2 GC/AG ZNF198 154 166 128 124 ↓
U2 GC/AG APRT 8 10 7 6.5 ↓
U12 GT/AG PLCd 18 19 21 9 ↓
U12 AT/AC SKT11 39 37 32 28 p<0.05 ↓
U12 AT/AC C3G 17 24 9 13 ↓
U12 AT/AG AP2A1 36 39 40 29 ↓
Significant differences obtained by the LSD test are highlighted in bold. A significant increase in splicing efficiency was observed
for GAPDH in PRPF31 severe cell lines. In contrast a significant decrease in splicing efficiency was observed for RPGR splicing
in the same cell line. In PRPF8 cell lines a significant decrease in splicing efficiency was seen for SKT11, as well as an overall
decline in splicing for all U12 introns and non-canonical U2 introns.
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Gene Controlratios for intron 3 of SKT11 with respect to controls (Figure 2).
AP2A1, PLC-delta, and C3G introns did not show statistically
significant differences between control and PRPF8 mutant
cell lines; however, a general trend could be seen toward a
decrease of splicing ratios in PRPF8 mutants compared to
controls for all U12 introns. This trend also extended to the
two noncanonical U2 introns. These data are summarized in
Table 4.
Multivariate  tests:  Multivariate  tests  were  performed  to
investigate these findings. These tests failed to ascertain the
apparent decrease in splicing ratios in PRPF8 mutant cells for
U12 introns. This could be due to the sample sizes being too
small,  or  to  the  parametric  test  relying  on  incorrect
assumptions. Therefore a bootstrap test was performed, in
which the data were resampled, a test statistic was computed,
and the results were compared to the data test statistic. The
one-sided p-value for the U12 introns comparing controls
versus PRPF8 mutants was 0.067, whereas the p-value for
controls versus PRPF31 severe was much higher (0.30). This
confirmed that the trend toward decreased splicing deficiency
seen for PRPF8 mutant cell lines (which just fell short of
significance) was not reproduced in PRPF31 mutant cell lines.
Analysis of splicing ratios under high metabolic demand: One
possible explanation for the retina-specific manifestations of
splicing-factor RP is the high metabolic rate of photoreceptors
[47] and the consequent inability of the mutated PRPF8 or
PRPF31 to cope with the accompanying splicing demands;
this might become especially apparent for rate-limiting U12
intron  splicing  [14].  To  investigate  whether  splicing  is
affected  during  periods  of  high  demand  on  the  splicing
apparatus, we starved control and patients’ cell lines of serum
for 24 h. The splicing efficiency was investigated by real-time
PCR following the reintroduction of serum (at 0, 2, 4, 6, 12,
24,  and  72  h),  which  would  be  expected  to  result  in  a
substantial increase in the rate of cell division and growth. No
significant differences were found (data not shown).
Study  of  the  splicing  of  transfected  retina-specific  gene,
Rom-1: In a further attempt to determine if splicing could be
affected  by  conditions  of  high  splicing  demand,  we
transfected cell lines with plasmids encoding ROM-1 (exon 1
to exon 2), both in the wild-type form and with mutations
introducing a noncanonical splice donor sites (canonical GT
mutated to noncanonical AT and GA). The spliced versus
unspliced ratios of all constructs were again measured by real-
time  RT–PCR.  No  significant  differences  in  splicing
efficiency between the control and splicing factor mutant cell
lines  for  any  of  these  constructs  were  detected  (data  not
shown).
DISCUSSION
These  experiments  aimed  to  distinguish  between  two
hypotheses: that splicing factor mutations cause RP due to a
retina-specific  defect,  either  in  splicing  or  in  some  other
function involving these proteins; or that splicing factor RP
results  from  a  defect  in  splicing  that  is  subpathological
elsewhere in the body but which leads to a cumulative defect
in the metabolically active, irreplaceable retinal tissue. To
distinguish between these hypotheses, we assayed the ratio of
spliced to unspliced RNA as a measure of splicing efficiency
in lymphoblastoid cell lines derived from splicing factor RP
patients and normal control cell lines. This assay was applied
to a series of introns representing a range of intron types.
Results  did  reveal  significant  differences  in  splicing
ratios in these cells, but these differences were not consistent
between  the  different  splicing  factor  genes.  In  cells  from
PRPF31-RP patients, we observed a decrease in the splicing
efficiency of RPGR intron 9 and an increase in the splicing
efficiency of GAPDH intron 7. These are both U2 introns with
canonical donor and acceptor sites. In contrast, cells from
patients with PRPF8-RP showed no significant differences in
splicing  ratios  for  U2  introns  but  showed  a  consistent
downward  trend  in  splicing  efficiency  of  all  U12  and
noncanonical U2 introns assayed (statistical significance was
only attained for intron 3 of STK11). Cells from asymptomatic
carriers  of  PRPF31  mutations  revealed  no  significant
differences  in  splicing  ratio  compared  with  control  cells,
consistent with the findings of Vithana et al. [43], who showed
that  high  expression  of  the  second  allele  of  PRPF31
compensated  for  the  haploinsufficiency.  The  lack  of
consistency between findings in the cell lines from patients
with the two different mutant genes for splicing factor may be
the result of the small number of cell lines assayed, together
with the relatively high level of individual variation in splicing
efficiency between cell lines.
The finding of a difference in splicing efficiency in an
intron  of  RPGR  may  be  significant.  RPGR  is  a  putative
guanine nucleotide exchange factor that has been localized to
the Golgi region [55], and is thought to be important for
maintaining  the  polarized  protein  distribution  across  the
connecting cilium of the photoreceptors [56]. Mutations in
RPGR (RP3, Xp21.1) are responsible for up to 70% of X-
linked retinitis pigmentosa [51] and also cause X-linked cone-
rod  dystrophy  (CORDX1)  [52]  and  atrophic  macular
degeneration  [53].  However,  RPGR  is  ubiquitously
expressed, and several alternatively spliced isoforms of RPGR
have been found in the eye and other tissues, resulting in
product sizes ranging between 5 and 20 kb [57,58]. One of
these isoforms contains a retina-specific exon, ORF15, which
has been found to be a mutational hotspot in RP patients [59,
60].  The intron  tested herein is present  in this and other
isoforms expressed in the eye, but is absent from others also
present  in  the  eye.  Correct  splicing  of  RPGR  may  be
particularly important in the retina; mutations in PRPF31 may
have a negative effect on the splicing of RPGR pre-mRNA,
which could potentially contribute to the RP phenotype in
these patients. In the light of this finding it may now be
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expressed genes which are mutated in RP.
The one significant difference in splicing between control
and PRPF8 mutant cells was found within the U12 intron-
containing  gene  STK11.  Furthermore,  although  no  other
significant differences were observed, there was a consistent
trend toward an overall decrease in splicing efficiency of all
U12 introns tested. U12 splicing is thought to be the rate-
limiting step in the processing of any transcript containing a
U12  intron  [14].  In  the  fast-metabolizing  retina,  with  a
corresponding high demand placed on the splicing machinery,
a reduction in splicing efficiency of U12 intron-containing
transcripts could become significant over time, while other
tissues remain unaffected. Microarray analysis by Gamundi
et al. [28] in PRPF8 mutant lymphoblastoid cell lines showed
downregulation of one U-12 type gene, SLC12A7, but failed
to ascertain a pattern of downregulation of the minor U12-
dependent splicing genes as a group. However that study used
microarray analysis to examine transcript levels, whereas this
study examined intron specific splicing efficiency, potentially
a more sensitive method for detecting such an effect.
It is also interesting to note that the splicing ratio of
GAPDH intron 7 was significantly increased in cells from
PRPF31-RP patients relative to controls. GAPDH, as well as
being a major enzyme of the glycolytic pathway, has several
other functions, such as regulation of gene expression [61].
More important, GAPDH has been found to have a role in the
apoptosis of retinal cells [62]. The endpoint in many forms of
retinal degeneration is apoptosis of the retinal photoreceptors,
so this difference could also contribute to the development of
an RP phenotype.
Given  the  relatively  small  number  of  cell  lines
investigated and the small number of splice sites chosen, the
substantial variation in splicing efficiency between cell lines
(control  and  disease  groups)  and  the  inconsistency  of
differences found between the different genes for RP, these
data must be interpreted with caution. Nevertheless, this study
has recorded statistically significant differences in splicing
efficiency  in  cell  lines  from  patients  with  two  different
mutated  genes  for  splicing-factor  RP.  This  favors  the
hypothesis that RP may indeed result from a global deficit in
splicing, detectable outside the retina, but which only causes
pathology in the retina. Further elucidation of the mechanisms
underlying splicing-factor RP will play an important role in
the search for therapeutic agents.
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